CANF News 5.31 Can-Fite Biopharma Ltd Sponsore (CANF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Can-Fite Biopharma Ltd Sponsore (CANF) 5.31 $CANF

Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma

Can-Fite Files 2013 Annual Report on Form 20-F
PR Newswire - Mon Mar 31, 1:28PM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-Fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.

Can-Fite to Present at the 9th International Congress of Autoimmunity
PR Newswire - Tue Mar 25, 6:00AM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.

Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
PR Newswire - Mon Mar 17, 6:00AM CDT
Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel.

Can-Fite BioPharma announces USD5m from private placement
M2 - Tue Mar 11, 7:14AM CDT
US-based biotechnology company Can-Fite BioPharma (Tel Aviv:CFBI.TA) (NYSE MKT:CANF) said on Monday that it has closed a USD5m private placement with healthcare institutional investors.

Can-Fite Completes $5 Million Private Placement
PR Newswire - Mon Mar 10, 11:44AM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million.

Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
PR Newswire - Mon Mar 03, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.

Can-Fite to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Thu Feb 27, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California.

Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
PR Newswire - Tue Feb 25, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Japan Patent Office (JPO) has granted a Japanese patent which bears the Patent No. 5467872 and is titled "Process for the Synthesis of IB-MECA". This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate. Under its patent rights, Can-Fite will have exclusive rights for the manufacturing of CF101 in Japan till 2028.

Can-Fite Provides Update on Key Milestones for 2014
PR Newswire - Tue Feb 18, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's development plan for 2014.

3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Feb 12, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.

Can-Fite Comments on Global Rheumatoid Arthritis Market Opportunity
PR Newswire - Tue Feb 11, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today commented on the overall growth of the global rheumatoid arthritis market opportunity and the potential impact for the Company's proprietary drug CF101.

Can-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer
PR Newswire - Thu Feb 06, 6:00AM CST
Can-Fite BioPharma (TASE: CFBI), (OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted.

5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.

Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Jan 08, 9:17AM CST
Biotech Stock Roundup: Amgen Data Looks Good, CANF Tumbles - Industry Outlook

Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.

Pipeline Setback at Can-Fite BioPharma, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 10:50AM CST
CF101 did not fare well in a phase III study which evaluated patients with moderate-to-severe dry eye syndrome.

Can-Fite BioPharma (CANF) Soars: Stock Zooms 17.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 24, 6:51AM CST
Can-Fite BioPharma Ltd. was a big mover last session, as its shares rose over 17% on the day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 147

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 124

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 250

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 58

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 126

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 62

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading

Top 5 Most Recently Viewed Articles

Eimskip's Q3 2025 Financial Overview and Future Outlook

Updated Category News Views 238

Eimskip's Third Quarter Performance Analysis The results for the third quarter of 2025 have presented challenges for Eimskip, as operations did not meet expectations. Revenues showed significant shifts, revealing both obstacles and opportunities in the company's journey. Operational Insights During Q3, Eimskip experienced a slight increase in liner shipping volumes,...

Continue Reading
Market Trends and Insights: The Bullish Moves on Block

Updated Category News Views 88

Examining Recent Bullish Moves on Block Recently, financial institutions have been making significant bullish strides into Block, a company known for its innovative payment services. Analysis of the options trading history for Block (NASDAQ: SQ) indicates a noticeable interest, with 16 unusual trades captured, providing insights into market direction and trader sentiment....

Continue Reading
Exploring the Soaring Online Poker Market Growth Trends

Updated Category News Views 157

Online Poker Market: A Surge on the Horizon The Global Online Poker Market is currently undergoing a transformative expansion, predicted to rise from USD 7.98 billion in 2024 to an impressive USD 37.19 billion by 2030. This notable growth reflects a compound annual growth rate (CAGR) of 29.24%, driven by advancements in technology such as enhanced smartphone capabilities,...

Continue Reading
Elevate Your Gaming with Jackbit's New Crypto Welcome Offer

Updated Category News Views 182

Jackbit’s New Welcome Bonus for Crypto Players As online gaming evolves, Jackbit Crypto Casino is launching an exciting new welcome bonus tailored specifically for cryptocurrency enthusiasts. Starting next year, all new players joining the Jackbit platform will enjoy the same welcome bonuses that traditional fiat customers have been taking advantage of. This bold move...

Continue Reading
Eli Lilly's Mounjaro Drug Set to Revolutionize Weight Loss in Hong Kong

Updated Category News Views 214

Eli Lilly to Launch Weight Loss Drug Mounjaro in Hong Kong Eli Lilly & Co. (NYSE: LLY) is poised to launch its well-regarded weight-loss medication, Mounjaro, in Hong Kong shortly. This marks an exciting milestone, as it positions Mounjaro to be the first of its kind available in the broader region of China. The anticipated launch follows recent reports indicating that...

Continue Reading